New Minicare Video, page-8

Toddski.. Below is a timeline i did a while back... this needs to be looked at in conjunction with when Philips took a year off first and then ended their Minicare/Troponin partnership with BioM ... as this lines up nicely with the below ann's from ADO..

This is all speculation but there are many other clues as to why we all think we know who POC1 is... and too many to list right now.. off to get some local Mooloolaba Prawns now .. .over an out..

4C OCT 2012
PAID POINT OF CARE PROJECT I
We are nearing the end of a paid project in the field of “point of care” testing. Whilst further improvements remain possible within the assessment period we have already met the primary objective of the project. Our collaboration partners are pleased with what has been developed thus far and they have requested us to send material to two of the groups working on the project for verification of the results.

4C JAN 2012
PAID POINT OF CARE PROJECT l
We successfully completed a paid project with a player in the POC field and the objectives of the project were met. Amongst Anteo scientists there is the belief that further gains remain possible. The technical aspects for the next phase of work with this company have been agreed. The financial details for this phase and what might follow are now being considered before work is commenced.

4C APR 2013
PAID POINT OF CARE PROJECT l
A second paid project with POC 1 commenced on 13th March. It is envisaged that the objectives agreed in this collaborative project will take 12 months to achieve and will require Anteo scientists to work in a European laboratory for a period. We have agreed that both parties will work in good faith to strike mutually acceptable terms, for payments to Anteo on commercial launch of the new device, by June. Our current work is being undertaken on a risk sharing basis with a view to enhancing returns on successful commercialization of the resulting product.

4C JUL 2013
PAID POINT OF CARE PROJECT l
The “Feasibility Study” Agreement, with a global healthcare company, is a paid collaborative project aiding the development of a novel Point of Care device. The objectives are scheduled to take 12 months to complete.
The feasibility work commenced on 13th March. Since then two Anteo scientists have worked for a period in the European laboratories of our partner, enhancing our knowledge of issues to be addressed at manufacturing scale and increasing the level of cooperation between the relevant teams. A shipment of equipment was received from the company that, amongst other things, allows us to manufacture the consumable component of the test to facilitate comparison of results between the centres, which allows us to provide our customer with a “ready-to-manufacture” solution. Formal project meetings are held every fortnight and there is almost daily bi-directional communication between the collaborators.
The Anteo scientists intend to provide an improved solution that clearly demonstrates the many advantages of Mix&Go beyond the project parameters.

4C OCT 2013
PAID POINT OF CARE PROJECT l
At the end of June we received a shipment of equipment and materials that would allow us to undertake many of the activities in our Brisbane laboratories that are performed in our partners laboratories. The work that we have undertaken has strengthened our belief that Mix&Go can provide critical elements required for a commercially successful product. Our work with Mix&Go has resolved issues with colloidal stability and consistency of reading the amount of analyte there is in a blood sample. Addressing both of these issues are a necessary precursors to improving sensitivity.
Two of our scientists are currently working at our partner’s facility. Part of their work will involve a head-to-head comparison of Mix&Go methods versus the conventional method. We anticipate that the results obtained in this work will provide us with a clear path for the remainder of the project.
It is generally held that Mix&Go is able to significantly enhance the sensitivity of assays. This is particularly important with assays, such as troponin, where an ability to detect down to very low levels can greatly improve clinical outcomes. Our work to date has been around developing stable and repeatable conditions and already we feel we have contributed meaningfully to the project. We believe our value will be further enhanced should we be able to successfully deliver improved sensitivity.